Welireg
Merck & Co.’s Welireg Notches Wins in Kidney Cancer Combo Studies
Welireg; kidney cancer; renal cell carcinoma; Keytruda; Lenvima; adjuvant setting; combination therapy; Phase 3 trials; progression-free survival; disease-free survival
ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns
Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial